Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Peter Crooks to Nicotinic Antagonists

This is a "connection" page, showing publications Peter Crooks has written about Nicotinic Antagonists.

 
Connection Strength
  
 
 
6.244
  
  1. Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol. 2014; 69:513-51.
    View in: PubMed
    Score: 0.457
  2. Zheng G, Zhang Z, Dowell C, Wala E, Dwoskin LP, Holtman JR, McIntosh JM, Crooks PA. Discovery of non-peptide, small molecule antagonists of a9a10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. Bioorg Med Chem Lett. 2011 Apr 15; 21(8):2476-9.
    View in: PubMed
    Score: 0.375
  3. Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2011 Jan 01; 21(1):88-91.
    View in: PubMed
    Score: 0.368
  4. Zhang Z, Pivavarchyk M, Subramanian KL, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2010 Feb 15; 20(4):1420-3.
    View in: PubMed
    Score: 0.346
  5. Zheng F, McConnell MJ, Zhan CG, Dwoskin LP, Crooks PA. QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum. Bioorg Med Chem. 2009 Jul 01; 17(13):4477-85.
    View in: PubMed
    Score: 0.331
  6. Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z, Bardo MT, Crooks PA. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv. 2009; 55:31-63.
    View in: PubMed
    Score: 0.323
  7. Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2008 Nov 01; 18(21):5753-7.
    View in: PubMed
    Score: 0.317
  8. Albayati ZA, Dwoskin LP, Crooks PA. Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos. 2008 Oct; 36(10):2024-9.
    View in: PubMed
    Score: 0.312
  9. Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, Crooks PA. Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6701-6.
    View in: PubMed
    Score: 0.297
  10. Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6734-8.
    View in: PubMed
    Score: 0.297
  11. Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke RL, Bardo MT, Crooks PA. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochem Pharmacol. 2007 Oct 15; 74(8):1271-82.
    View in: PubMed
    Score: 0.292
  12. Zheng F, Bayram E, Sumithran SP, Ayers JT, Zhan CG, Schmitt JD, Dwoskin LP, Crooks PA. QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorg Med Chem. 2006 May 01; 14(9):3017-37.
    View in: PubMed
    Score: 0.263
  13. Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1863-7.
    View in: PubMed
    Score: 0.233
  14. Crooks PA, Ayers JT, Xu R, Sumithran SP, Grinevich VP, Wilkins LH, Deaciuc AG, Allen DD, Dwoskin LP. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1869-74.
    View in: PubMed
    Score: 0.233
  15. Maggio SE, Saunders MA, Baxter TA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Slack RD, Newman AH, Bell RL, Bardo MT. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. Psychopharmacology (Berl). 2018 05; 235(5):1439-1453.
    View in: PubMed
    Score: 0.152
  16. Beckmann JS, Meyer AC, Pivavarchyk M, Horton DB, Zheng G, Smith AM, Wooters TE, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP. r-bPiDI, an a6?2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochem Res. 2015 Oct; 40(10):2121-30.
    View in: PubMed
    Score: 0.127
  17. Peng C, Kimbrell MR, Tian C, Pack TF, Crooks PA, Fifer EK, Papke RL. Multiple modes of a7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents. Mol Pharmacol. 2013 Sep; 84(3):459-75.
    View in: PubMed
    Score: 0.110
  18. Wala EP, Crooks PA, McIntosh JM, Holtman JR. Novel small molecule a9a10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats. Anesth Analg. 2012 Sep; 115(3):713-20.
    View in: PubMed
    Score: 0.102
  19. Holtman JR, Dwoskin LP, Dowell C, Wala EP, Zhang Z, Crooks PA, McIntosh JM. The novel small molecule a9a10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. Eur J Pharmacol. 2011 Nov 30; 670(2-3):500-8.
    View in: PubMed
    Score: 0.097
  20. Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP. bPiDI: a novel selective a6?2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol. 2011 May; 163(2):346-57.
    View in: PubMed
    Score: 0.095
  21. Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol. 2010 Aug 01; 80(3):402-9.
    View in: PubMed
    Score: 0.088
  22. Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. Biochem Pharmacol. 2009 Oct 01; 78(7):889-97.
    View in: PubMed
    Score: 0.084
  23. Dwoskin LP, Smith AM, Wooters TE, Zhang Z, Crooks PA, Bardo MT. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol. 2009 Oct 01; 78(7):732-43.
    View in: PubMed
    Score: 0.083
  24. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. Eur J Pharmacol. 2008 Dec 28; 601(1-3):103-5.
    View in: PubMed
    Score: 0.080
  25. Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, Manda VK, Ayers JT, Zhang Z, Deaciuc AG, McIntosh JM, Crooks PA, Bardo MT. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J Pharmacol Exp Ther. 2008 Aug; 326(2):563-76.
    View in: PubMed
    Score: 0.077
  26. Papke RL, Dwoskin LP, Crooks PA, Zheng G, Zhang Z, McIntosh JM, Stokes C. Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras. Neuropharmacology. 2008 Jun; 54(8):1189-200.
    View in: PubMed
    Score: 0.077
  27. Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier. J Pharmacol Exp Ther. 2008 Jan; 324(1):244-50.
    View in: PubMed
    Score: 0.074
  28. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology. 2007 Mar; 52(3):755-63.
    View in: PubMed
    Score: 0.070
  29. Wilkins LH, Miller DK, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of antagonists at alpha 4 beta 2* nicotinic acetylcholine receptors: inhibition of S(-)-nicotine-evoked 86Rb+ efflux from rat thalamic synaptosomes. AAPS J. 2006 Jan 13; 7(4):E922-30.
    View in: PubMed
    Score: 0.066
  30. Sumithran SP, Crooks PA, Xu R, Zhu J, Deaciuc AG, Wilkins LH, Dwoskin LP. Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity. AAPS J. 2005 Aug 29; 7(1):E201-17.
    View in: PubMed
    Score: 0.064
  31. Zheng G, Dwoskin LP, Deaciuc AG, Zhu J, Jones MD, Crooks PA. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem. 2005 Jun 02; 13(12):3899-909.
    View in: PubMed
    Score: 0.063
  32. Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther. 2003 Sep; 306(3):1011-20.
    View in: PubMed
    Score: 0.055
  33. Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors. J Pharmacol Exp Ther. 2003 Jan; 304(1):400-10.
    View in: PubMed
    Score: 0.053
  34. Ayers JT, Dwoskin LP, Deaciuc AG, Grinevich VP, Zhu J, Crooks PA. bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors. Bioorg Med Chem Lett. 2002 Nov 04; 12(21):3067-71.
    View in: PubMed
    Score: 0.053
  35. Wilkins LH, Haubner A, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther. 2002 Jun; 301(3):1088-96.
    View in: PubMed
    Score: 0.051
  36. Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks PA, Dwoskin LP, Bell RL, Bardo MT. An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic a6?2* antagonist r-bPiDI. Drug Alcohol Depend. 2018 12 01; 193:154-161.
    View in: PubMed
    Score: 0.040
  37. Pivavarchyk M, Smith AM, Zhang Z, Zhou D, Wang X, Toyooka N, Tsuneki H, Sasaoka T, McIntosh JM, Crooks PA, Dwoskin LP. Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release. Eur J Pharmacol. 2011 May 11; 658(2-3):132-9.
    View in: PubMed
    Score: 0.023
  38. Middleton LS, Crooks PA, Wedlund PJ, Cass WA, Dwoskin LP. Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation. Synapse. 2007 Mar; 61(3):157-65.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.